4SC AG (FSCGF.PK) Wednesday said it has been granted a key patent for its lead anti-cancer compound resminostat in Japan. The patent covers the composition of matter of resminostat, pharmaceutical compositions comprising resminostat and its therapeutic use in cancer and other therapeutic areas.
The company is engaged in the discovery and development of targeted small molecule drugs for autoimmune diseases and cancer. In April, 4SC granted an exclusive license to Yakult Honsha for the development and commercialization of resminostat in Japan. Hepatocellular carcinoma, the most common type of liver cancer, has a particularly high incidence in Japan.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org